NEW YORK, Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance ...
Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics This is a randomized, double-blind, placebo-controlled, multi-center Phase 2a dose-ranging study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results